CN112585130A - 蛋白酶体活性增强化合物 - Google Patents

蛋白酶体活性增强化合物 Download PDF

Info

Publication number
CN112585130A
CN112585130A CN201980055145.2A CN201980055145A CN112585130A CN 112585130 A CN112585130 A CN 112585130A CN 201980055145 A CN201980055145 A CN 201980055145A CN 112585130 A CN112585130 A CN 112585130A
Authority
CN
China
Prior art keywords
optionally substituted
group
alkyl
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980055145.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·卡伦
S·豪克
M·福利
B·泰特
M·黑贝莱因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protein Balance Therapy Co ltd
Original Assignee
Protein Balance Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Balance Therapy Co ltd filed Critical Protein Balance Therapy Co ltd
Publication of CN112585130A publication Critical patent/CN112585130A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN201980055145.2A 2018-06-27 2019-06-27 蛋白酶体活性增强化合物 Pending CN112585130A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690554P 2018-06-27 2018-06-27
US62/690,554 2018-06-27
PCT/US2019/039562 WO2020006269A1 (en) 2018-06-27 2019-06-27 Proteasome activity enhancing compounds

Publications (1)

Publication Number Publication Date
CN112585130A true CN112585130A (zh) 2021-03-30

Family

ID=67297405

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980055145.2A Pending CN112585130A (zh) 2018-06-27 2019-06-27 蛋白酶体活性增强化合物

Country Status (5)

Country Link
US (2) US11746098B2 (enExample)
EP (1) EP3814336A1 (enExample)
JP (2) JP7551087B2 (enExample)
CN (1) CN112585130A (enExample)
WO (1) WO2020006269A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699394A (zh) * 2022-05-24 2022-07-05 中山大学附属第一医院 用于肝癌放疗增敏的药物组合物及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006269A1 (en) * 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706750A (en) * 1966-05-17 1972-12-19 Whitefin Holding Sa Pyrrylaminoketone derivatives
CN102844313A (zh) * 2010-01-28 2012-12-26 哈佛大学校长及研究员协会 提高蛋白酶体活性的组合物和方法
CN103635230A (zh) * 2011-05-12 2014-03-12 普罗蒂斯特斯治疗公司 蛋白内稳态调节剂
WO2014116228A1 (en) * 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1142508A (en) * 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
BR9907228A (pt) 1998-01-23 2000-10-24 Nat Jewish Med & Res Center Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
BRPI0416216A (pt) 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
EP3441090A1 (en) 2005-05-17 2019-02-13 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
MX2007015602A (es) 2005-06-08 2008-02-21 Amicus Therapeutics Inc Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas.
WO2007098229A2 (en) 2006-02-21 2007-08-30 Michigan State University Geldanamycin derivatives and method of use thereof
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
EP2024745B1 (en) 2006-05-16 2015-07-08 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
MX2007006175A (es) 2006-05-24 2009-02-16 Amicus Therapeutics Inc Sal de tartrato de isofagomina y metodos de uso.
JP5303458B2 (ja) 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
US8785490B2 (en) * 2010-04-09 2014-07-22 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012078909A1 (en) 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Thiazolpyrimidine proteostasis regulators
US20120214824A1 (en) 2010-12-08 2012-08-23 Bradley Tait Proteostasis regulators
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
AU2013202373B2 (en) 2012-01-25 2016-04-14 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CA2861464C (en) 2012-01-25 2018-03-06 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
WO2014210159A1 (en) 2013-06-26 2014-12-31 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
CN104478780B (zh) * 2014-11-17 2017-04-19 华东师范大学 酰基吡咯类小分子有机化合物及其衍生物、用途及其制备方法
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105477A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971855A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971835A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3325474A1 (en) 2015-07-24 2018-05-30 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
WO2017040606A1 (en) 2015-08-31 2017-03-09 Proteostasis Therapeutics, Inc. Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders
RU2752567C2 (ru) 2015-10-06 2021-07-29 Протеостазис Терапьютикс, Инк. Соединения, композиции и способы для модуляции cftr
EP3393465A1 (en) 2015-12-22 2018-10-31 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
US10662207B2 (en) 2016-04-07 2020-05-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US20190154661A1 (en) 2016-05-09 2019-05-23 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
ES2954658T3 (es) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
EP3532469A1 (en) 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
CA3041676A1 (en) 2016-10-26 2018-05-03 Daniel Parks Pyridazine derivatives, compositions and methods for modulating cftr
CA3041675A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
WO2018201126A1 (en) 2017-04-28 2018-11-01 Proteostasis Therapeutics, Inc. 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
US20210369749A1 (en) 2017-10-06 2021-12-02 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2020006269A1 (en) * 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706750A (en) * 1966-05-17 1972-12-19 Whitefin Holding Sa Pyrrylaminoketone derivatives
CN102844313A (zh) * 2010-01-28 2012-12-26 哈佛大学校长及研究员协会 提高蛋白酶体活性的组合物和方法
CN103635230A (zh) * 2011-05-12 2014-03-12 普罗蒂斯特斯治疗公司 蛋白内稳态调节剂
WO2014116228A1 (en) * 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MONICA BOSELLI等: "An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons", JOURNAL OF BIOLOGICAL CHEMISTRY *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699394A (zh) * 2022-05-24 2022-07-05 中山大学附属第一医院 用于肝癌放疗增敏的药物组合物及其应用

Also Published As

Publication number Publication date
US20210188802A1 (en) 2021-06-24
US11746098B2 (en) 2023-09-05
WO2020006269A1 (en) 2020-01-02
JP2024112835A (ja) 2024-08-21
EP3814336A1 (en) 2021-05-05
US20240116894A1 (en) 2024-04-11
JP7551087B2 (ja) 2024-09-17
JP2021530465A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
US6936638B2 (en) Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
EP2806876A2 (en) Proteasome activity enhancing compounds
AU2013202373A1 (en) Proteasome activity enhancing compounds
EP2707101B1 (en) Proteostasis regulators
EP2806875B1 (en) Proteasome activity modulating compounds
WO2012154880A1 (en) Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
JP2024112835A (ja) プロテアソーム活性増強化合物
US12138265B2 (en) Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
CN112585132B (zh) 蛋白酶体活性增强化合物
AU2013202368A1 (en) Proteasome activity modulating compounds
ES2935615T9 (es) Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa
WO2012078909A1 (en) Thiazolpyrimidine proteostasis regulators
HK40049558A (en) Proteasome activity enhancing compounds
KR20210111787A (ko) 전사 인자 eb 폴리펩티드 수준을 증가시키기 위한 방법 및 물질
KR20040026462A (ko) 신규 피라졸로피리미딘계 사이클린 의존카이네이즈(ｃｄｋ) 저해제 및 그의 제조방법
HK1195525B (en) Proteostasis regulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049558

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts

Applicant after: Umaniti

Address before: Massachusetts

Applicant before: PROTEOSTASIS THERAPEUTICS, Inc.